US 11,939,324 B2
Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
Johan Gerard Griffioen, Kessel-Lo (BE); Katrien Princen, Heverlee (BE); Tom Francois L. Van Dooren, Koningshooikt (BE); Arnaud Didier Marie Marchand, Bierbeek (BE); Amuri Kilonda, Boutersem (BE); Sara Allasia, Mechelen (BE); and Patrick Chaltin, Zetrud-Lumay (BE)
Assigned to reMYND N.V., Leuven (BE); and Katholieke Universiteit Leuven, Leuven (BE)
Filed by reMYND N.V., Leuven (BE); and Katholieke Universiteit Leuven, Leuven (BE)
Filed on Nov. 22, 2022, as Appl. No. 18/058,109.
Application 18/058,109 is a continuation of application No. 16/612,096, granted, now 11,548,881, previously published as PCT/EP2018/062199, filed on May 11, 2018.
Claims priority of application No. 17170674 (EP), filed on May 11, 2017.
Prior Publication US 2023/0099111 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/12 (2006.01); A61P 25/28 (2006.01)
CPC C07D 413/12 (2013.01) [A61P 25/28 (2018.01)] 12 Claims
 
1. A method of treatment of a disease comprising administering an effective amount of a compound of formula (I), or a tautomer thereof, wherein the disease is selected from the group consisting of epilepsy, neurodegenerative disorders, pain disorders, anxiety disorders, depression, bipolar disorder, psychosis, drug withdrawal, tobacco withdrawal, memory loss, dementia, schizophrenia, and panic; and wherein the compound of formula (I), or a tautomer thereof, has the structure:

OG Complex Work Unit Chemistry
wherein:
R1 is selected from the group consisting of hydrogen; F, Cl, and Br;
R2 is selected from the group consisting of hydrogen, F, Cl, and Br;
R3 is selected from the group consisting of hydrogen, F, Cl, and Br;
R4 is selected from the group consisting of hydrogen, F, Cl, and Br;
R5 is selected from the group consisting of hydrogen, F, Cl, and Br;
with the proviso that at least one of R1, R2, R3, R4 or R5 is not hydrogen;
with the proviso that said compound of formula (I) is not N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]isoxazole-3-carboxamide,
or a solvate, a hydrate, a salt, or a prodrug thereof.